Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 13 people enrolled
- Started
- 22 Mar 2023
- Ended
- 2 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- palmitoylethanolamide
- Placebo
- Record updated
- 5 November 2024
Who can take part
- Age
- 40 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adults aged 40 to 80
- English speaking
- Self reported diagnosis of osteoarthritis in one or both knees
- Self-reported average knee pain over the past month at least 4 out of 10 on a 0-10 numeric rating scale
- Agreement to abstain from all osteoarthritis pain medication (such as non-steroidal anti-inflammatory drugs or narcotics) and use only acetaminophen as a rescue medication when needed
- Can pass an evaluation to sign consent
Who cannot take part
- Knee surgery in past 12 months or total knee replacement
- Oral or intra-articular glucocorticoid use in the prior 3 months; intra-articular hyaluronate use in the prior 6 months
- Any of the following conditions: chronic kidney disease stage 3-5, unstable angina, congestive heart failure, cancer or cancer treatment (except skin)
- Allergy to oat, coconut, citrus, olive, or sunflower oils, or maltodextrin
- Inflammatory arthritis (eg. Rheumatoid arthritis)
- Knee injury in past 6 months
- Pregnant or breastfeeding
- enrolled in other knee OA rehabilitation programs or clinical trials
- Opioid use in the past month
Where in United States
- University of Maryland, BaltimoreBaltimore, United States
About the trial
What the trial wants to find out
The purposes of this 1-year proof of feasibility and acceptability pilot study are twofold. First to determine if participants with knee osteoarthritis (KOA) will comply with taking palmitoylethanolamide (PEA) dietary supplement for 6 weeks and adhere to taking it as directed. Second is to gain preliminary data to elucidate mechanisms (protein signatures, inflammatory markers and neurobiological signaling pathways) by which PEA, a lipid-based endocannabinoid, works to alter pain sensitivity in adults with KOA. In the simplest terms possible, we need to provide evidence that PEA changes the protein signature in order to provide evidence to establish mechanism.
The 2 groups in the trial
- palmitoylethanolamide (PEA)Treatment being tested
Palmitoylethanolamide (PEA) is a lipid based endocannabinoid dietary supplement currently marketed.
Treatment: palmitoylethanolamide
- PlaceboPlacebo, for comparison
A similar size and shaped capsule containing maltodextrin will be used as a placebo comparator.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 November 2024